- Home
- SRV vs GNLX Comparison
SRV vs GNLX Comparison
Compare SRV & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRV
- GNLX
- Stock Information
- Founded
- SRV 2007
- GNLX 2001
- Country
- SRV United States
- GNLX United States
- Employees
- SRV N/A
- GNLX N/A
- Industry
- SRV Finance Companies
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- SRV Finance
- GNLX Health Care
- Exchange
- SRV Nasdaq
- GNLX Nasdaq
- Market Cap
- SRV 123.3M
- GNLX 103.6M
- IPO Year
- SRV N/A
- GNLX 2023
- Fundamental
- Price
- SRV $42.29
- GNLX $2.27
- Analyst Decision
- SRV
- GNLX Strong Buy
- Analyst Count
- SRV 0
- GNLX 4
- Target Price
- SRV N/A
- GNLX $18.25
- AVG Volume (30 Days)
- SRV 33.9K
- GNLX 142.7K
- Earning Date
- SRV 01-01-0001
- GNLX 11-14-2024
- Dividend Yield
- SRV 13.38%
- GNLX N/A
- EPS Growth
- SRV N/A
- GNLX N/A
- EPS
- SRV N/A
- GNLX N/A
- Revenue
- SRV N/A
- GNLX $8,000.00
- Revenue This Year
- SRV N/A
- GNLX N/A
- Revenue Next Year
- SRV N/A
- GNLX N/A
- P/E Ratio
- SRV N/A
- GNLX N/A
- Revenue Growth
- SRV N/A
- GNLX N/A
- 52 Week Low
- SRV $30.73
- GNLX $1.60
- 52 Week High
- SRV $44.30
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- SRV 40.18
- GNLX 38.68
- Support Level
- SRV $44.46
- GNLX $2.13
- Resistance Level
- SRV $45.14
- GNLX $2.80
- Average True Range (ATR)
- SRV 1.10
- GNLX 0.20
- MACD
- SRV -0.45
- GNLX -0.04
- Stochastic Oscillator
- SRV 31.62
- GNLX 14.21
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.